Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

September 03, 2015 7:27 PM ET

Healthcare Providers and Services

Company Overview of Joslin Diabetes Center, Inc.

Company Overview

Joslin Diabetes Center, Inc. operates a diabetes treatment, research, and education institution. It offers research programs for preventing and curing type 1 and type 2 diabetes and their long-term complications. The company also provides diabetes care services for adult and pediatric patients. In addition, it develops and markets programs, products, and services for the availability of the company’s knowledge and expertise to people with diabetes and the clinicians caring for them. Joslin Diabetes Center, Inc. was founded in 1898 and is headquartered in Boston, Massachusetts.

One Joslin Place

Boston, MA 02215

United States

Founded in 1898





Key Executives for Joslin Diabetes Center, Inc.

Chief Executive Officer, President and Trustee
Age: 64
Chief Financial Officer
Age: 57
Chief Scientific Officer, Senior Vice President and Trustee
Chief Academic Officer
Senior Vice President of Medical Affairs
Compensation as of Fiscal Year 2015.

Joslin Diabetes Center, Inc. Key Developments

David DiFiore Joins Joslin Diabetes Center as Vice President of Clinical Operations

Joslin Diabetes Center announced that David DiFiore has joined its executive team as Vice President of Clinical Operations. In his new position, Mr. DiFiore will be responsible for all clinical operations to ensure Joslin continues delivering cutting-edge diabetes care and research. This study was funded by the National Institutes of Health. Prior to joining Joslin, Mr. DiFiore was Director of Finance and Clinical Services for the Department of Pediatrics at Boston Medical Center, overseeing the administration, finance and operations of more than 100 physicians and the pediatric service line, including ambulatory operations, emergency and inpatient services. He previously served as a Clinical Manager at Lahey Hospital & Medical Center, where he directed operational components of Cardiology, Vascular Medicine, Cardiothoracic Surgery, Vascular Surgery, Electrocardiology, Echocardiology and Cardiac Rehabilitation. He is a member of the Medical Group Management Association (MGMA) and Healthcare Financial Management Association (HFMA).

Joslin Diabetes Center and Daegu-Gyeongbuk Free Economic Zone Sign MoU to Explore Opportunities to Collaborate

Joslin Diabetes Center and Daegu-Gyeongbuk Free Economic Zone have signed a memorandum of understanding formalizing their mutual strong commitment to navigate avenues for potential partnership. The MoU signing is an important step towards establishing a partnership that will allow Joslin to potentially establish a physical presence in the Daegu-Gyeongbuk area, bringing Joslin’s mission of preventing, treating and curing diabetes to the region. There were an estimated 2.7 million cases of diabetes in the Republic of Korea in 2014.

MedImmune and Joslin Diabetes Center Announce New Research Collaboration Focused on Advancing Metabolic Disease Research

MedImmune and Joslin Diabetes Center announced a three-year research collaboration to develop new medicines for the treatment of diabetes, obesity, and related metabolic disorders. MedImmune and Joslin researchers will work collaboratively on research projects to identify new drug candidates. Three initial projects have been identified, focusing on several key areas including protecting and regenerating the insulin producing beta cells, increasing the caloric utilization of fat depots ('beiging' white fat or expanding brown fat), and replicating the beneficial effects of bariatric surgery pharmacologically. The collaboration is structured with the potential for more projects to be added as new compelling science is identified. Under the terms of the agreement, MedImmune will provide research funding to Joslin and bring drug development expertise and capabilities to complement Joslin's early metabolic disease research competencies and clinical care infrastructure. MedImmune has the option to license development and commercial rights to projects emerging from the collaboration.

Similar Private Companies By Industry

Company Name Region
O'Mara Scientific Inc. United States
Emergency Medcial Transport Inc. United States
Unity Dental Service Plan Inc. United States
Radiological Service Training Institute, Inc. United States
Memphis Lung Physicians, PC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Joslin Diabetes Center, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at